Compare KNRX & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNRX | CTSO |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 45.9M |
| IPO Year | 2025 | N/A |
| Metric | KNRX | CTSO |
|---|---|---|
| Price | $1.54 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 17.4K | ★ 124.7K |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,820,365.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $7.26 |
| Revenue Next Year | N/A | $9.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.00 | 23.89 |
| 52 Week Low | $1.25 | $0.60 |
| 52 Week High | $4.00 | $1.61 |
| Indicator | KNRX | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.78 |
| Support Level | N/A | $0.61 |
| Resistance Level | N/A | $0.77 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 48.19 |
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.